summarize the patients current clinical picture

Patient Thomas Court (TEST-THOMAS-COURT) is currently active with a latest assessment dated June 6, 2025. The primary phenotype identified is mitochondrial dysfunction, with a secondary phenotype of neuroinflammation. The patient is in the recovery stage and is currently in an intake-only phase, with a confidence level of 54. The top scores for the patient are as follows: mitochondrial dysfunction at 67, neuroinflammation at 48, and mold CIRS pattern at 34 [1]. This summary is for decision support purposes only and not a directive.